Search

everythinglearnresearchcommunity

for

Search:↓

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

CRISPR/Cas systems show promise for cancer treatment by targeting miRNAs, but delivery and specificity challenges remain.

NXC736 significantly reduced hair loss in mice with alopecia areata.

COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.

iPSC-derived artificial platelets show promise for consistent and effective regenerative therapies.

GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.

Early recognition and a multidisciplinary approach are crucial for effectively managing complex autoimmune conditions like SLE with CAPS and AHA.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

LHTric-1 is a specific antibody useful for studying hair and nail formation.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

A woman developed psoriasis after taking certolizumab pegol, improving after stopping the drug and starting other treatments.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

Dual TCR Treg cells are common in mouse tissues and vary by location.

A new engineered treatment shows promise in curing heart fibrosis.

CD146 + mesenchymal stem cells are more effective for treating premature ovarian failure.

Adalimumab improved folliculitis decalvans in most patients.

Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

A group has developed therapies that show promise for treating cancer and various other conditions.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

Biosimilars lower costs but don't significantly improve access.

RADA-PDGF2 hydrogel speeds up wound healing and is safe for use.